Extended Data Fig. 4: The identified natural compounds inhibit early stages of SARS-CoV-2 infection in primary human bronchial epithelial cells.
From: Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2
(a) Experimental procedure. (b) Immunofluorescence staining of SARS-CoV-2 in the primary human bronchial (HBEpC) epithelial cells. Gamabufotalin, bruceine A or anisomycin were added at different timepoints, at 200 nM, MOI = 1. Nucleocapsid is shown in green. Spike is shown in red. Scale bar: 50 μm. (c) Quantification of the immunofluorescence images in HBEpC. The data are shown as mean ± s.d. (n = 3). P value, two-sided non-paired t-test between compound- and DMSO-treated groups. **P < 0.01. NS: not significant. Exact P values: starting from gamabufotalin anti-N: 0.0036, 0.0057, 0.69, 0.0036, 0.0046, 0.21, 0.0036, 0.0043, 0.11; starting from gamabufotalin anti-S: 0.0039, 0.0059, 0.86, 0.0039, 0.0050, 0.12, 0.0039, 0.0047, 0.083.
